Evotec SE (EVO)

NASDAQ: EVO · IEX Real-Time Price · USD
10.35
+0.14 (1.37%)
At close: Sep 22, 2023, 4:00 PM
10.79
+0.44 (4.25%)
After-hours: Sep 22, 2023, 7:17 PM EDT
1.37%
Market Cap 3.67B
Revenue (ttm) 799.41M
Net Income (ttm) -186.87M
Shares Out 354.37M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE 89.29
Dividend n/a
Ex-Dividend Date n/a
Volume 19,011
Open 10.42
Previous Close 10.21
Day's Range 10.22 - 10.49
52-Week Range 7.80 - 13.49
Beta 0.98
Analysts Buy
Price Target 14.33 (+38.45%)
Earnings Date Nov 8, 2023

About EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol ... [Read more]

Sector Healthcare
IPO Date Nov 4, 2021
Employees 4,952
Stock Exchange NASDAQ
Ticker Symbol EVO
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $14.33, which is an increase of 38.45% from the latest price.

Price Target
$14.33
(38.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates

NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/...

26 days ago - Accesswire

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2...

4 weeks ago - Accesswire

Evotec Provides Update on Financial Impact of Cyber-Attack

HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it is adjusting its guidance for the fiscal y...

2 months ago - Accesswire

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPE...

Other symbols: BMY
2 months ago - Accesswire

Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVE...

2 months ago - Accesswire

Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme

PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC HAMBURG, GERMAN...

3 months ago - Accesswire

Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items

ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY REPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023 HAMBURG, GERMANY / ACCESSWIRE / June 20, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MD...

3 months ago - Accesswire

Evotec Presents Sustainability Strategy

TOGETHER FOR A SUSTAINABLE AND EFFICIENT SHARED R&D ECONOMY PRECISION MEDICINES AND BETTER ACCESS TO BIOTHERAPEUTICS ESG PERFORMANCE REPORT HIGHLIGHTS SUSTAINABILITY AS A COMPETITIVE ADVANTAGE IN CHAL...

3 months ago - Accesswire

Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics

$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM...

4 months ago - Accesswire

Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

PUBLICATION OF ANNUAL REPORT 2022: "AHEAD OF THE CURVE" QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED HAMBURG, GERMANY / AC...

4 months ago - Accesswire

Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz

HHAMBURG, GERMANY / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that Evotec's Seattle-based subsidiary...

4 months ago - Accesswire

Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS D...

Other symbols: NVS
4 months ago - Accesswire

Evotec SE Provides Update on Cyber Attack

Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts HAMBURG, GERMANY / ACCESSWIRE / April 10, 2023 / Evotec SE (FFSE:EVT, MDAX/TecDAX, ...

5 months ago - Accesswire

Cyber Attack on Evotec

HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occ...

6 months ago - Accesswire

Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TE...

Other symbols: BMY
6 months ago - Accesswire

Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDU...

6 months ago - Accesswire

Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis

GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PRO...

6 months ago - Accesswire

Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023

HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesd...

6 months ago - Accesswire

Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE ...

6 months ago - Accesswire

Evotec Receives € 150 m Loan from European Investment Bank

FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN ...

8 months ago - Accesswire

Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership

EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MUL...

8 months ago - Accesswire

Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer

HAMBURG, GERMANY / ACCESSWIRE / February 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company's Supervisory Board has appoi...

8 months ago - Accesswire

Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies

STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/...

8 months ago - Accesswire

Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb

THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMB...

Other symbols: BMY
10 months ago - Accesswire

Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2...

11 months ago - Accesswire